Further, many employers (as high as 59% of employers with at least 5,000 workers) that offered such coverage said that use of GLP-1 medications was higher than expected, and 66% of the largest employers said that covering such drugs for weight loss had a significant impact on their health plans prescription drug spending
Whilst great advancements have been made over the last century with regard to understanding the regulation of metabolic homeostasis which has yielded new therapeutic options for diseases such as T2D, it is unlikely that highly desirable more efficacious treatments will be developed for metabolic disorders until the complex systemic regulation of metabolic homeostasis becomes more intricately understood
doi: 10.1016/j.physbeh.2006.05.048 60 PlamboeckAVeedfaldSDeaconCFHartmannBWettergrenASvendsenLBet al
In humans, intravenous cocaine injection was shown to decrease plasma GLP-1 concentration, while endogenous GLP-1 was associated with subjective responses to cocaine 90
Glucagon-like peptide-1 in diabetes care: can glycaemic control be achieved without nausea and vomiting
While real-world data on the level of adherence to dual GLP1-RA/GIP agonists are not available to date, some considerations can be drawn from available clinical trials and experiences with other pharmacological classes